Memantine in moderate-to-severe Alzheimer's disease.

By S. Bleich, J. Wiltfang, J. Kornhuber. New England Journal of Medicine, 2003

987 citations recorded by the source corpus.

Subfields: Emergency Medicine, Neurology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/0c21319405683a844298adf97b2af142cdfad7b3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Emergency Medicine

1. C. Parsons
2. A. Stöffler
3. W. Danysz

In Neurology

1. Michael D. Geschwind
2. Michael G. Erkkinen
3. C. Parsons
4. Mee‐Ohk Kim
5. A. Stöffler
6. W. Danysz
7. S. Lipton

In Rheumatology

1. C. Parsons
2. A. Stöffler
3. W. Danysz

Citations in the corpus

• Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. (2007, methodology): “Reisberg et al. (2003) 2003 Review on proposed MOA of memantine.”
• Education and Dementia in the Context of the Cognitive Reserve Hypothesis: A Systematic Review with Meta-Analyses and Qualitative Analyses (2012, background): “Autopsy studies have found that 10% to 40% of individuals with mild to moderate brain pathology did not manifest clinical symptoms of dementia [9], [10].”
• Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. (2004, methodology): “Similar to the finding in the present trial, discontinuation rates because of adverse events in the monotherapy study were lower in patients receiving memantine than in those receiving placebo (10% vs 17%, respectively).(7) These trials support the efficacy of memantine for patients with moderate to”
• Tau pathology in Alzheimer disease and other tauopathies. (2005, background): “…affinity NMDA receptor antagonist, which improves mental function and the quality of daily living of patients with moderate to severe AD [148,149], restores the okadaic acid-induced inhibition of PP-2A activity, the abnormal hyperphosphorylation of tau at Ser-262 and the associated…”
• Oxidative stress in neurodegenerative diseases (2012, background): “For example, Memantine slows the development of AD and is of modest benefit to patients in the moderately severe to severe range of the disease by targets the N-methyl-Daspartate receptor [104] .”
• Neurodegenerative diseases and oxidative stress (2004, background): “Memantine slows the development of the disease and is of modest benefit to patients in the moderately severe to severe range of the diseas”
• Mechanisms of tau-induced neurodegeneration (2009, positive): “This effect of memantine might be responsible for the therapeutic effect of this drug in moderate to severe stage AD patients and a reduction in the phosphotau in their CSF [59, 158].”
• Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond (2006, neutral): “Memantine was recently approved by the European Union and the US FDA for the treatment of moderate-to-severe Alzheimer's disease, and might show efficacy for more mild Alzheimer's disease and vascular dementi”
• Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “…believed to work by suppressing glutamatemediated excitotoxicity, has been shown to reduce clinical deterioration on several scales in patients with moderate-to-severe AD compared with controls (Howard et al. 2012; Reisberg et al. 2003), but not in patients with mild disease (McShane et al. 2006).”